Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLSTICE phase 2 study of VIR-2218 and VIR-3434 in chronic hepatitis D
NL-OMON53856Phase 2Recruiting
- Sponsor
- Vir Biotechnology
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of elebsiran and tobevibart in Chronic Viral Hepatitis B With Delta-Agent and Chronic Hepatitis B (CHB) (3 arms), sponsored by Vir Biotechnology. Primary endpoints: Composite virologic and biochemical response at Week 24 and Safety. Started Nov 2023; status: recruiting.
02
Drugs
elebsirantobevibart
03
Conditions
Chronic Viral Hepatitis B With Delta-AgentChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON53856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53856.